Trial software group raises $45M to push decentralized studies; $120M SPAC makes its way to Nasdaq
After watching the entire clinical trial process go through a major makeover during the pandemic, another software outfit is making a play to help developers get on the cutting edge of trial design and decentralized execution.
Hoboken, NJ-based Castor has just raised $45 million to fund development of software intended to scale up their “direct-to-patients” approach globally. This new round brings their total funding to $65 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.